Showing results (11-20 of 4,635) with videos related to
Sort By:
Pageof 464
Anti-Cancer Drugs|January 26, 2011
Targeted therapies in malignant pleural mesothelioma: a review of clinical studiesLaurent Greillier, Sabine Marco, Fabrice BarlesiAnti-Cancer Drugs|January 15, 2011
Murine orthotopic model for the assessment of chemoradiotherapeutic interventions in rectal cancerSergio Huerta, Xiaohuan Gao, Debabrata SahaAnti-Cancer Drugs|October 13, 2010
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patientsRobert K Sylvester, Preston Steen, John M Tate, et al.Anti-Cancer Drugs|December 17, 2010
Additive effects of trastuzumab and genistein on human breast cancer cellsClaus Lattrich, Julia Lubig, Anette Springwald, et al.Anti-Cancer Drugs|November 5, 2010
Synthesis and activity evaluation of a new bestatin derivative LYP2 as an aminopeptidase N inhibitorYepeng Luan, Qiang Wang, Ning Liu, et al.Anti-Cancer Drugs|January 11, 2011
New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicalsPavel Soucek, Eliska Kondrova, Josef Hermanek, et al.Anti-Cancer Drugs|March 2, 2011
In-vitro/in-vivo studies of the biodegradable poly-(D,L-lactide-co-glycolide) microspheres of a novel luteinizing hormone-releasing hormone antagonist for prostate cancer treatmentLina Du, Xingguo Mei, Chenyun Wang, et al.Anti-Cancer Drugs|March 2, 2011
A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinomaHiraku Yodono, Kunihiro Matsuo, Atsushi ShinoharaAnti-Cancer Drugs|March 2, 2011
Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancerRyan S Raddin, Christine M Walko, Young E WhangAnti-Cancer Drugs|August 19, 2010
Glycolytic flux occurs in Drosophila melanogaster recovering from camptothecin treatmentRodney Hull, Monde McMillan NtwasaPageof 464